FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2927903318> ?p ?o ?g. }

• W2927903318 endingPage "12" @default.
• W2927903318 startingPage "1" @default.
• W2927903318 abstract "Circulating apolipoprotein-AII (apoAII-) ATQ/AT is a potential useful biomarker for early stage pancreatic ductal adenocarcinoma (PDAC), but its clinical significance in PDAC patients remains uncertain. The aim of the current study was to assess the usefulness of apoAII-ATQ/AT as a surrogate for the effect of chemoradiotherapy (CRT) and its association with pancreatic exocrine disorder, paying attention to morphological changes of the pancreas.In the 264 PDAC patients who were enrolled in our CRT protocol, the following parameters were measured at specified time points before and after CRT: serum levels of albumin, total cholesterol, and amylase as indices of pancreatic exocrine function, serum levels of CA19-9, and the pancreatic morphology including tumor size (TS), main pancreatic duct diameter (MPDD), and pancreatic parenchymal volume excluding tumor volume (PPV) by using computed tomography (CT) images. Plasma apoAII-ATQ/AT levels were simultaneously measured with enzyme-linked immunosorbent assay in 4 healthy volunteers and the 44 PDAC patients before and after CRT. Plasma apoAII-ATQ/AT levels after CRT were analyzed according to small/large-MPDD and small/large-PPV groups based on their median values after CRT. Plasma samples after CRT were measured after incubation with human pancreatic juice (PJ) to examine the relevance between apoAII isoforms and circulating pancreatic enzymes.The serum levels of albumin, amylase, CA19-9, TS, MPDD, and PPV after CRT were significantly lower than those before CRT (median, before vs. after: 3.9 g/dl, 74 U/l, 180.2 U/ml, 58.1 mm, 4.0 mm, and 34.8 ml vs. 3.8, 59, 43.5, 55.6, 3.6, and 25.2). ApoAII-ATQ/AT levels (median, μg/ml) of PDAC patients before CRT were significantly lower than those in healthy volunteers: 32.9 vs. 61.2, and unexpectedly those after CRT significantly decreased: 14.7. The reduction rate of apoAII-ATQ/AT was not correlated with those of CA19-9 and TS, indicating that apoAII-ATQ/AT is not a tumor-specific marker. On the other hand, the patient group with large MPDD and small PV exhibited higher apoAII-ATQ levels than those with small MPDD and large PPV. The incubation of plasma samples after CRT with PJ did not alter apoAII-ATQ/AT and apoAII-AT levels but significantly decreased apoAII-ATQ levels, suggesting that circulating pancreatic enzymes markedly influenced apoAII-ATQ levels.ApoAII-ATQ/AT levels are not useful for evaluation of clinical effect of CRT for PDAC, but apoAII isoforms are very useful to assess pancreatic exocrine disorder because pancreatic atrophy and insufficient secretion of circulating pancreatic enzymes are considered likely to influence apoAII-ATQ levels." @default.
• W2927903318 created "2019-04-11" @default.
• W2927903318 creator A5003938029 @default.
• W2927903318 creator A5012415507 @default.
• W2927903318 creator A5015214616 @default.
• W2927903318 creator A5027959930 @default.
• W2927903318 creator A5037435759 @default.
• W2927903318 creator A5045237664 @default.
• W2927903318 creator A5048705484 @default.
• W2927903318 creator A5054973025 @default.
• W2927903318 creator A5058419340 @default.
• W2927903318 creator A5060592514 @default.
• W2927903318 creator A5061737621 @default.
• W2927903318 creator A5067861967 @default.
• W2927903318 creator A5068397684 @default.
• W2927903318 creator A5072040203 @default.
• W2927903318 creator A5081945875 @default.
• W2927903318 date "2019-04-04" @default.
• W2927903318 modified "2023-10-18" @default.
• W2927903318 title "Clinical Significance of Plasma Apolipoprotein-AII Isoforms as a Marker of Pancreatic Exocrine Disorder for Patients with Pancreatic Adenocarcinoma Undergoing Chemoradiotherapy, Paying Attention to Pancreatic Morphological Changes" @default.
• W2927903318 cites W1496455032 @default.
• W2927903318 cites W1965567580 @default.
• W2927903318 cites W1985637841 @default.
• W2927903318 cites W1990383064 @default.
• W2927903318 cites W1993062205 @default.
• W2927903318 cites W1994177577 @default.
• W2927903318 cites W2005869765 @default.
• W2927903318 cites W2010769173 @default.
• W2927903318 cites W2012005360 @default.
• W2927903318 cites W2012147729 @default.
• W2927903318 cites W2026822462 @default.
• W2927903318 cites W2043138141 @default.
• W2927903318 cites W2070013745 @default.
• W2927903318 cites W2071226692 @default.
• W2927903318 cites W2089578068 @default.
• W2927903318 cites W2131698397 @default.
• W2927903318 cites W2138541357 @default.
• W2927903318 cites W2139880626 @default.
• W2927903318 cites W2140624144 @default.
• W2927903318 cites W2147717981 @default.
• W2927903318 cites W2267469086 @default.
• W2927903318 cites W2321528110 @default.
• W2927903318 cites W2344019383 @default.
• W2927903318 cites W2410209614 @default.
• W2927903318 cites W2524080253 @default.
• W2927903318 cites W2642712341 @default.
• W2927903318 cites W58571634 @default.
• W2927903318 cites W993424279 @default.
• W2927903318 doi "https://doi.org/10.1155/2019/5738614" @default.
• W2927903318 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6475573" @default.
• W2927903318 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31080824" @default.
• W2927903318 hasPublicationYear "2019" @default.
• W2927903318 type Work @default.
• W2927903318 sameAs 2927903318 @default.
• W2927903318 citedByCount "8" @default.
• W2927903318 countsByYear W29279033182019 @default.
• W2927903318 countsByYear W29279033182020 @default.
• W2927903318 countsByYear W29279033182021 @default.
• W2927903318 countsByYear W29279033182022 @default.
• W2927903318 countsByYear W29279033182023 @default.
• W2927903318 crossrefType "journal-article" @default.
• W2927903318 hasAuthorship W2927903318A5003938029 @default.
• W2927903318 hasAuthorship W2927903318A5012415507 @default.
• W2927903318 hasAuthorship W2927903318A5015214616 @default.
• W2927903318 hasAuthorship W2927903318A5027959930 @default.
• W2927903318 hasAuthorship W2927903318A5037435759 @default.
• W2927903318 hasAuthorship W2927903318A5045237664 @default.
• W2927903318 hasAuthorship W2927903318A5048705484 @default.
• W2927903318 hasAuthorship W2927903318A5054973025 @default.
• W2927903318 hasAuthorship W2927903318A5058419340 @default.
• W2927903318 hasAuthorship W2927903318A5060592514 @default.
• W2927903318 hasAuthorship W2927903318A5061737621 @default.
• W2927903318 hasAuthorship W2927903318A5067861967 @default.
• W2927903318 hasAuthorship W2927903318A5068397684 @default.
• W2927903318 hasAuthorship W2927903318A5072040203 @default.
• W2927903318 hasAuthorship W2927903318A5081945875 @default.
• W2927903318 hasBestOaLocation W29279033181 @default.
• W2927903318 hasConcept C121608353 @default.
• W2927903318 hasConcept C126322002 @default.
• W2927903318 hasConcept C134018914 @default.
• W2927903318 hasConcept C142724271 @default.
• W2927903318 hasConcept C144369459 @default.
• W2927903318 hasConcept C170835558 @default.
• W2927903318 hasConcept C181199279 @default.
• W2927903318 hasConcept C2776737053 @default.
• W2927903318 hasConcept C2778764654 @default.
• W2927903318 hasConcept C2779960720 @default.
• W2927903318 hasConcept C2780210213 @default.
• W2927903318 hasConcept C2781182431 @default.
• W2927903318 hasConcept C2781197716 @default.
• W2927903318 hasConcept C55493867 @default.
• W2927903318 hasConcept C63363279 @default.
• W2927903318 hasConcept C71924100 @default.
• W2927903318 hasConcept C86803240 @default.
• W2927903318 hasConcept C90924648 @default.
• W2927903318 hasConceptScore W2927903318C121608353 @default.
• W2927903318 hasConceptScore W2927903318C126322002 @default.
• W2927903318 hasConceptScore W2927903318C134018914 @default.

• next